Advair, Serevent add "black box"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's asthma treatments Advair Diskus (fluticasone/salmeterol) and Serevent (salmeterol) labeling is revised to include "black box" warnings on an increased risk of asthma-related deaths in salmeterol-treated patients. Warnings for both products state that patients receiving salmeterol on top of a usual asthma regimen "showed a small but significant increase in asthma-related deaths" vs. placebo, an Aug. 14 FDA "Talk Paper" states. The effect was more pronounced in African American patients. The finding comes from GSK's Salmeterol Multicenter Asthma Research Trial (SMART); the firm alerted physicians in January that it had halted the study due to the findings and enrollment difficulties. "It is not known whether the findings seen with Serevent…would apply to Advair," Advair's labeling states. FDA is considering the possibility of a beta agonist class effect...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.